Soligenix nabs $26.3m US contract to develop radiation exposure drug OrbeShield
This article was originally published in Scrip
Executive Summary
Shares of Soligenix soared as high as 23.6% on 19 September on news the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the biotech a contract worth up to $26.3m to advance the development of its oral drug OrbeShield (beclomethasone 17,21-dipropionate) as a medical countermeasure (MCM) against gastrointestinal acute radiation syndrome (GI ARS).